Diagnosis of Hyperosmolar Hyperglycemic Syndrome (HHS): A Comprehensive Guide

Hyperosmolar hyperglycemic syndrome (HHS) is a serious complication of diabetes mellitus, predominantly type 2, characterized by severe hyperglycemia, hyperosmolarity, and dehydration, without significant ketoacidosis. Early and accurate Diagnosis Of Hhs is critical due to its potentially life-threatening nature and high mortality rate compared to diabetic ketoacidosis (DKA). This article provides a comprehensive guide for healthcare professionals on the diagnosis of HHS, encompassing its clinical presentation, evaluation, and differential diagnosis.

Understanding Hyperosmolar Hyperglycemic Syndrome

HHS arises from a relative insulin deficiency and insulin resistance, leading to reduced glucose utilization and increased hepatic glucose production. This results in profound hyperglycemia, often exceeding 600 mg/dL, and a significant increase in serum osmolality, typically above 320 mOsm/L. The osmotic diuresis induced by hyperglycemia leads to severe dehydration, a hallmark of HHS, which is often more pronounced than in DKA. While both HHS and DKA are hyperglycemic crises, the key differentiator in diagnosis of HHS is the absence of significant ketoacidosis, a condition prominent in DKA due to absolute insulin deficiency.

Historically known as hyperosmolar hyperglycemic nonketotic coma (HONK), the nomenclature has evolved to HHS as coma is not always present. The timely diagnosis of HHS is paramount as delayed recognition and treatment can lead to significant morbidity and mortality.

Etiology and Risk Factors Influencing HHS Diagnosis

Recognizing the predisposing factors is crucial for prompt diagnosis of HHS, especially in at-risk individuals. Infections are the most common precipitating factor, accounting for 50-60% of cases, including pneumonia, urinary tract infections, and sepsis. These infections trigger a stress response, releasing counter-regulatory hormones that exacerbate hyperglycemia and dehydration.

Certain medications can also contribute to the development of HHS, complicating the diagnosis of HHS if medication history is not carefully considered. These include thiazide diuretics, corticosteroids, beta-blockers, and atypical antipsychotics, all of which can impair glucose metabolism or induce dehydration.

Cardiovascular events such as myocardial infarction or stroke can also precipitate HHS by triggering stress hormone release. Other risk factors that should raise suspicion and prompt consideration of diagnosis of HHS include:

• Type 2 Diabetes: HHS is predominantly seen in type 2 diabetes, often in older individuals with a history of poorly controlled diabetes or undiagnosed diabetes.
• Obesity: Insulin resistance associated with obesity increases the risk.
• Age: Older adults are more susceptible due to decreased thirst mechanism and potential comorbidities.
• Impaired Renal Function: Reduced ability to excrete glucose can worsen hyperglycemia and hyperosmolarity.
• Limited Access to Water: Conditions that restrict fluid intake increase dehydration risk.
• Dementia or Cognitive Impairment: Patients may not recognize or communicate thirst effectively.

Clinical Presentation: Key Indicators for HHS Diagnosis

The clinical presentation of HHS is often insidious, evolving over days to weeks, which can delay diagnosis of HHS compared to the more rapid onset of DKA. A detailed history and thorough physical examination are essential for accurate and timely diagnosis of HHS.

History: Key historical features to elicit include:

• Diabetes History: Known type 2 diabetes, history of poor glycemic control, or newly diagnosed diabetes.
• Precipitating Factors: Recent infections, medication changes, cardiovascular events.
• Symptoms: Polyuria, polydipsia, weakness, lethargy, visual disturbances, and neurological changes.
• Fluid Intake: Reduced fluid intake or impaired access to fluids.

Physical Examination: Physical findings suggestive of HHS and crucial for diagnosis of HHS include:

• Dehydration: Dry mucous membranes, poor skin turgor (though less reliable in obese patients), delayed capillary refill, sunken eyes. Orthostatic hypotension and tachycardia are common signs of volume depletion.
• Neurological Status: Altered mental status is a hallmark of HHS, ranging from confusion and lethargy to seizures and coma. Focal neurological deficits, such as hemiparesis or aphasia, can also occur, mimicking stroke. The severity of neurological symptoms correlates with serum osmolality.
• Vitals: Tachycardia, hypotension, and tachypnea (though less pronounced than in DKA unless there is underlying acidosis).
• General Appearance: Patients typically appear ill and weak.

It is important to note that while the absence of Kussmaul breathing (deep, rapid respirations) and fruity breath (ketone odor) are often cited as differentiating HHS from DKA, these are not absolute indicators for diagnosis of HHS. Some overlap in symptoms can occur, necessitating laboratory evaluation for definitive diagnosis of HHS.

Diagnostic Evaluation: Confirming HHS Diagnosis

Laboratory investigations are essential to confirm the diagnosis of HHS and differentiate it from other hyperglycemic emergencies and conditions causing altered mental status. The diagnostic criteria for HHS, established by the American Diabetes Association and international guidelines, are based on specific laboratory findings:

• Plasma Glucose: Greater than 600 mg/dL (33.3 mmol/L). This is a primary criterion for diagnosis of HHS, reflecting the severe hyperglycemia.
• Effective Plasma Osmolality: Greater than 320 mOsm/kg. Calculated using the formula: 2[Na+] + [Glucose] (mg/dL)/18. Elevated osmolality is a defining feature and reflects the hyperosmolar state.
• Absence of Significant Ketoacidosis: This is a crucial differentiator from DKA. Typically defined by:
  • Arterial pH: Greater than 7.30.
  • Serum Bicarbonate: Greater than 18 mEq/L.
  • Minimal or Absent Ketones: Serum or urine ketones are typically absent or only mildly elevated.

Essential Laboratory Tests for HHS Diagnosis:

1. Blood Glucose: Immediate fingerstick glucose is the first step, followed by venous or arterial blood glucose measurement for accurate values. Hourly monitoring is crucial during initial treatment.

2. Serum Electrolytes: Comprehensive metabolic panel including sodium, potassium, chloride, bicarbonate, magnesium, and phosphate.

   • Sodium: Often falsely low (pseudohyponatremia) due to osmotic water shift. Corrected sodium should be calculated.
   • Potassium: Can be initially normal or elevated due to insulin deficiency and extracellular shift, but total body potassium is usually depleted.
   • Bicarbonate: Typically normal or mildly reduced, distinguishing HHS from DKA.

3. Serum Osmolality: Measured or calculated. Elevated osmolality is a key diagnostic criterion.

4. Blood Urea Nitrogen (BUN) and Creatinine: Elevated due to dehydration and prerenal azotemia, reflecting volume depletion.

5. Arterial Blood Gases (ABG): To assess pH and rule out significant acidosis. pH > 7.30 is typical in HHS.

6. Ketones: Serum and urine ketone measurements are essential to differentiate HHS from DKA. Ketones should be minimal or absent in HHS.

7. Hemoglobin A1c (HbA1c): Provides information on long-term glycemic control and can help identify new-onset diabetes.

8. Complete Blood Count (CBC): May show leukocytosis if infection is the precipitating factor. Hemoconcentration can elevate hemoglobin and hematocrit.

9. Urine Analysis: Glycosuria is expected. Ketonuria should be minimal or absent. Urine specific gravity will be high, indicating dehydration.

10. Serum Enzymes (Creatinine Kinase, Transaminases): May be elevated due to dehydration and stress.

11. Magnesium and Phosphate: Levels may be low and should be monitored and replaced as needed during treatment.

Diagnostic Algorithm for HHS:

In a patient presenting with hyperglycemia and altered mental status, the following steps are recommended for diagnosis of HHS:

1. Rapid Glucose Measurement: Fingerstick glucose to confirm hyperglycemia.
2. Assess Clinical Presentation: Evaluate for dehydration, neurological status, and precipitating factors.
3. Laboratory Evaluation: Obtain comprehensive metabolic panel, serum osmolality, ABG, ketones, BUN, creatinine, CBC, HbA1c, and urine analysis.
4. Calculate Effective Osmolality: Confirm osmolality > 320 mOsm/kg.
5. Assess Acid-Base Status and Ketones: Rule out significant ketoacidosis (pH > 7.30, bicarbonate > 18 mEq/L, minimal ketones).
6. Differential Diagnosis: Consider and exclude other causes of hyperglycemia and altered mental status.
7. Confirm HHS Diagnosis: If criteria are met, establish diagnosis of HHS and initiate prompt treatment.

Differential Diagnosis in HHS

The differential diagnosis for HHS includes other conditions that can cause altered mental status and hyperglycemia. Accurate diagnosis of HHS requires careful consideration of these alternatives:

Conditions Causing Altered Mental Status:

• Hypoglycemia: Though paradoxical in a hyperglycemic crisis, hypoglycemia must always be rapidly excluded in any patient with altered mental status.
• Diabetic Ketoacidosis (DKA): The most critical differential diagnosis. DKA is distinguished by metabolic acidosis and significant ketonemia.
• Hyponatremia and Hypernatremia: Electrolyte imbalances can cause neurological dysfunction.
• Hyperammonemia: Consider in patients with liver disease.
• Sepsis: Infection can cause both altered mental status and hyperglycemia.
• Uremic Encephalopathy: Renal failure can lead to altered mental status and may coexist with diabetes.
• Toxic ingestions: Alcohol, drugs, and other toxins.
• Stroke or Transient Ischemic Attack (TIA): Focal neurological deficits in HHS can mimic stroke. Neuroimaging may be needed to differentiate.

Conditions Causing Hyperglycemia:

• Stress Hyperglycemia: Hyperglycemia due to stress from illness or surgery, but typically less severe than HHS and without significant hyperosmolarity.
• Diabetes Insipidus: Causes polyuria and hypernatremia but not hyperglycemia.

A detailed history, physical examination, and appropriate laboratory investigations are crucial to differentiate HHS from these conditions and ensure accurate diagnosis of HHS.

Conclusion: The Importance of Timely and Accurate HHS Diagnosis

The diagnosis of HHS is a critical step in managing this life-threatening complication of diabetes. Prompt recognition based on clinical presentation, risk factors, and definitive laboratory criteria is essential for initiating timely and appropriate treatment. Distinguishing HHS from DKA and other conditions causing altered mental status is paramount to guide management and improve patient outcomes. Healthcare professionals must maintain a high index of suspicion for diagnosis of HHS in at-risk individuals presenting with hyperglycemia and altered mental status, ensuring rapid evaluation and intervention to reduce morbidity and mortality associated with this serious condition.

References

1.Pasquel FJ, Umpierrez GE. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care. 2014 Nov;37(11):3124-31. [PMC free article: PMC4207202] [PubMed: 25342831]

2.American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010 Jan;33 Suppl 1(Suppl 1):S62-9. [PMC free article: PMC2797383] [PubMed: 20042775]

3.Röder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. Exp Mol Med. 2016 Mar 11;48(3):e219. [PMC free article: PMC4892884] [PubMed: 26964835]

4.Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997 Jul;20(7):1183-97. [PubMed: 9203460]

5.Milionis HJ, Elisaf MS. Therapeutic management of hyperglycaemic hyperosmolar syndrome. Expert Opin Pharmacother. 2005 Sep;6(11):1841-9. [PubMed: 16144505]

6.Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul;32(7):1335-43. [PMC free article: PMC2699725] [PubMed: 19564476]

7.Wachtel TJ, Silliman RA, Lamberton P. Predisposing factors for the diabetic hyperosmolar state. Arch Intern Med. 1988 Mar;148(3):747. [PubMed: 3341875]

8.Wachtel TJ, Silliman RA, Lamberton P. Prognostic factors in the diabetic hyperosmolar state. J Am Geriatr Soc. 1987 Aug;35(8):737-41. [PubMed: 3611564]

9.Wachtel TJ, Silliman RA, Lamberton P. Predisposing factors for the diabetic hyperosmolar state. Arch Intern Med. 1987 Mar;147(3):499-501. [PubMed: 3827427]

10.McDonnell CM, Pedreira CC, Vadamalayan B, Cameron FJ, Werther GA. Diabetic ketoacidosis, hyperosmolarity and hypernatremia: are high-carbohydrate drinks worsening initial presentation? Pediatr Diabetes. 2005 Jun;6(2):90-4. [PubMed: 15963036]

11.Kitabchi AE, Wall BM. Diabetic ketoacidosis. Med Clin North Am. 1995 Jan;79(1):9-37. [PubMed: 7808097]

12.Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, Ellis SE, O’Sullivan PS. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med. 1991 Nov-Dec;6(6):495-502. [PubMed: 1765864]

13.Wachtel TJ. The diabetic hyperosmolar state. Clin Geriatr Med. 1990 Nov;6(4):797-806. [PubMed: 2224747]

14.Wilson DR, D’Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res. 2003 Jan 01;59(1):1-6. [PubMed: 12413635]

15.Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des. 2004;10(18):2219-29. [PubMed: 15281897]

16.Bradford AL, Crider CC, Xu X, Naqvi SH. Predictors of Recurrent Hospital Admission for Patients Presenting With Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. J Clin Med Res. 2017 Jan;9(1):35-39. [PMC free article: PMC5127213] [PubMed: 27924173]

17.Trence DL, Hirsch IB. Hyperglycemic crises in diabetes mellitus type 2. Endocrinol Metab Clin North Am. 2001 Dec;30(4):817-31. [PubMed: 11727401]

18.MacIsaac RJ, Lee LY, McNeil KJ, Tsalamandris C, Jerums G. Influence of age on the presentation and outcome of acidotic and hyperosmolar diabetic emergencies. Intern Med J. 2002 Aug;32(8):379-85. [PubMed: 12162394]

19.Macaulay MB. Hyperosmolar non-ketotic diabetes. Postgrad Med J. 1971 Apr;47(546):191-6. [PMC free article: PMC2467093] [PubMed: 5576486]

20.Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, Wall BM. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001 Jan;24(1):131-53. [PubMed: 11194218]

21.Kitabchi AE, Nyenwe EA. Hyperglycemic crises in diabetes mellitus: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endocrinol Metab Clin North Am. 2006 Dec;35(4):725-51, viii. [PubMed: 17127143]

22.Delaney MF, Zisman A, Kettyle WM. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am. 2000 Dec;29(4):683-705, V. [PubMed: 11149157]

23.Nugent BW. Hyperosmolar hyperglycemic state. Emerg Med Clin North Am. 2005 Aug;23(3):629-48, vii. [PubMed: 15982538]

24.Rosenbloom AL. Hyperglycemic crises and their complications in children. J Pediatr Endocrinol Metab. 2007 Jan;20(1):5-18. [PubMed: 17315523]

25.Gordon EE, Kabadi UM. The hyperglycemic hyperosmolar syndrome. Am J Med Sci. 1976 May-Jun;271(3):252-68. [PubMed: 779472]

26.Conley SB. Hypernatremia. Pediatr Clin North Am. 1990 Apr;37(2):365-72. [PubMed: 2184402]

27.Arieff AI, Carroll HJ. Hyperosmolar nonketotic coma with hyperglycemia: abnormalities of lipid and carbohydrate metabolism. Metabolism. 1971 Jun;20(6):529-38. [PubMed: 4996168]

28.Zeitler P, Haqq A, Rosenbloom A, Glaser N., Drugs and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. J Pediatr. 2011 Jan;158(1):9-14, 14.e1-2. [PubMed: 21035820]

29.Hockaday TD, Alberti KG. Diabetic coma. Clin Endocrinol Metab. 1972 Nov;1(3):751-88. [PubMed: 4204136]

30.Arieff AI, Kleeman CR. Studies on mechanisms of cerebral edema in diabetic comas. Effects of hyperglycemia and rapid lowering of plasma glucose in normal rabbits. J Clin Invest. 1973 Mar;52(3):571-83. [PMC free article: PMC302295] [PubMed: 4685082]